Neoadjuvant use of pertuzumab in HER2-positive breast cancer: Hint of lesser benefit

(Institute for Quality and Efficiency in Health Care) In contrast to the use in advanced unresectable breast cancer, no positive effects have been proven. However, more patients discontinue treatment, particularly due to cardiac disorders.